Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
A holder of AORT common stock, Marshall S. Stanton, has filed a Form 144 notice to sell 47,376 shares of common stock through Fidelity Brokerage Services on the NYSE. The issuer has 47,374,939 common shares outstanding, which shows the planned sale is small relative to the total share count.
The shares to be sold were acquired on 11/21/2025 through the exercise of two stock options originally granted on 02/23/2022 and 11/08/2022, paid for in cash. The form also reports recent sales by Stanton over the past three months, including 15,276 shares sold on 11/20/2025 for gross proceeds of $674,833.49.
Marshall S. Stanton has filed a Rule 144 notice to sell 15,276 shares of AORT common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 674,833.49 and total shares outstanding of 47,374,939.
The shares to be sold were recently acquired through a mix of restricted stock vesting and option exercises, including blocks of 3,917, 3,986, and 3,985 shares from restricted stock and 2,033 and 1,355 shares from options granted in 2022.
Over the past three months, Stanton has also sold 2,566 and 4,993 AORT common shares for gross proceeds of 114,492.10 and 228,970.50. By signing the notice, he represents that he does not know of any material adverse nonpublic information about the issuer’s operations.
Artivion, Inc. (AORT) director share sale disclosed
A director of Artivion, Inc. reported selling 4,200 shares of the company’s common stock on 11/18/2025 at a weighted average price of $45.098 per share, with individual sale prices ranging from $44.89 to $45.295. After this transaction, the director beneficially owns 27,189 shares directly. The price range disclosure indicates multiple trades were executed to complete the total sale.
The notice reports a planned sale of 4,200 shares of common stock of AORT by a holder under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $189,413.28 and an approximate sale date of 11/18/2025. These shares were acquired as restricted stock from the issuer on 06/06/2024, with no separate cash payment described. As context, the filing states that 47,374,939 shares of the issuer’s common stock were outstanding at the time referenced.
Artivion, Inc. (AORT) senior vice president and general counsel Jean F. Holloway reported option exercises and related stock sales in November 2025. On November 14, 2025, she exercised options to acquire 6,393 shares of common stock at $29.62 per share and sold 6,393 shares at $45.00 per share, leaving 169,801 shares owned directly, then 163,408 shares after the sale. On November 17, 2025, she exercised options for 6,394 shares at $29.62 and sold 6,394 shares at $45.17, with 169,802 shares shown after the exercise and 163,408 shares directly owned after the sale.
The derivative table shows these transactions came from stock options granted with a $29.62 exercise price and an expiration date of March 5, 2026. The filing notes that the option exercises and subsequent sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options vested in equal annual installments beginning March 5, 2020.
Artivion, Inc. (AORT) reported insider share transactions by its Chief Commercial Officer on Form 4. On November 14, 2025 and November 17, 2025, the officer exercised stock options to acquire 6,393 and 6,394 shares of common stock, respectively, at an exercise price of $29.62 per share. On the same dates, the officer sold the same numbers of shares at prices of $44.67 and $45.17 per share. After these transactions, the officer directly owned 198,842 shares of Artivion common stock. The filing notes that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options originally began vesting on March 5, 2020.
Artivion, Inc. (AORT) reported an insider stock sale by a senior officer. On 11/17/2025, the company’s VP and Chief Accounting Officer sold 6,000 shares of common stock in an open market transaction at a weighted average price of $45.73 per share, with trade prices ranging from $45.605 to $45.91. After this transaction, the officer beneficially owns 135,380 shares of Artivion common stock, held directly. The filing notes that detailed price breakdowns for each trade within the reported range are available upon request.
AORT filed a Form 144 indicating an intended sale of restricted or control securities. The filing covers a planned sale of 6,394 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $288,816.98. These shares are part of a class with 47,374,939 shares outstanding, and the approximate sale date is 11/17/2025 on the NYSE.
The seller acquired these shares on 11/17/2025 through an option granted on 03/05/2019, paid in cash. Over the prior three months, John E. Davis reported additional sales of common shares: 3,373 shares on 11/10/2025 for $150,499.55, 6,563 shares on 11/13/2025 for $300,968.02, and 6,393 shares on 11/14/2025 for $285,575.31.
AORT received a Form 144 notice indicating that Amy D. Horton plans to sell 6,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 11/17/2025. The filing notes that there were 47,374,939 common shares outstanding at the time referenced in the form.
The shares to be sold were originally acquired via restricted stock vesting from the issuer as compensation in February 2017, in two grants of 3,491 and 2,509 shares. Over the past three months, the seller has already sold 1,789 and 3,482 common shares, generating gross proceeds of $79,823.21 and $159,678.60, respectively.
Artivion, Inc. (AORT) has a shareholder filing a notice to sell company stock under Rule 144. The filing covers the planned sale of 6,394 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $288,816.98. These shares were acquired on 11/17/2025 through the cash exercise of an employee stock option originally granted on 03/05/2019. The filing notes that 47,374,939 common shares were outstanding. Over the prior three months, the same seller, Jean F. Holloway, reported selling additional common shares in three transactions totaling 22,154 shares for gross proceeds of $1,013,674.66.